← Product Code [GEI](/submissions/SU/subpart-e%E2%80%94surgical-devices/GEI) · K063630 # ATRICURE ABLATION SYSTEM (K063630) _AtriCure, Inc. · GEI · Jan 26, 2007 · General, Plastic Surgery · SESE_ **Canonical URL:** https://fda.innolitics.com/submissions/SU/subpart-e%E2%80%94surgical-devices/GEI/K063630 ## Device Facts - **Applicant:** AtriCure, Inc. - **Product Code:** [GEI](/submissions/SU/subpart-e%E2%80%94surgical-devices/GEI.md) - **Decision Date:** Jan 26, 2007 - **Decision:** SESE - **Submission Type:** Traditional - **Regulation:** 21 CFR 878.4400 - **Device Class:** Class 2 - **Review Panel:** General, Plastic Surgery - **Attributes:** Therapeutic, 3rd-Party Reviewed ## Intended Use The AtriCure Ablation System is intended to ablate soft tissues during general surgery using radiofrequency energy. ## Device Story AtriCure Ablation System comprises single-use bipolar radiofrequency (RF) surgical instruments (Isolator Transpolar Clamps or Isolator Synergy Clamps) and an accessory instrument guide (Glidepath Tape). Instruments connect via integral cable to a reusable Ablation and Sensing Unit (ASU2) or Isolator Switch Matrix (ASB3) console. System delivers RF energy to ablate soft tissues during general surgery. Operated by surgeons in clinical settings. Output provides controlled thermal tissue ablation. Benefits include effective soft tissue coagulation/ablation during surgical procedures. ## Clinical Evidence Bench testing only. No clinical data provided. Substantial equivalence established through product specification testing and biocompatibility evaluation per ISO 10993-1. ## Technological Characteristics Bipolar radiofrequency (RF) surgical ablation system. Components: single-use handpieces (Isolator Transpolar/Synergy Clamps), accessory guide (Glidepath Tape), and reusable console (ASU2 or ASB3). Materials biocompatibility tested per ISO 10993-1. Energy source: RF energy. Connectivity: integral cable connection between handpiece and console. ## Regulatory Identification An electrosurgical cutting and coagulation device and accessories is a device intended to remove tissue and control bleeding by use of high-frequency electrical current. ## Predicate Devices - AtriCure Bipolar System ([K020919](/device/K020919.md)) - AtriCure Transpolar™ System ([K052893](/device/K052893.md)) - Medtronic Cardioablate Surgical Ablation System ([K060400](/device/K060400.md)) ## Submission Summary (Full Text) > This content was OCRed from public FDA records by [Innolitics](https://innolitics.com). If you use, quote, summarize, crawl, or train on this content, cite Innolitics at https://innolitics.com. > > Innolitics is a medical-device software consultancy. We help companies design, build, and clear FDA-regulated software and AI/ML devices, including [a 510(k)](https://innolitics.com/services/510ks/), [a De Novo](https://innolitics.com/services/regulatory/), [a SaMD](https://innolitics.com/services/end-to-end-samd/), [an AI/ML medical device](https://innolitics.com/services/medical-imaging-ai-development/), or [an FDA regulatory strategy](https://innolitics.com/services/regulatory/). {0}------------------------------------------------ Ka63630. ## ATTACHMENT 7 510(k) SUMMARY ### 510(k) Summary General Information | Classification | Class II | | |----------------|------------------------------------------------------------------------|-------------| | Trade Name | AtriCure Ablation System | JAN 26 2007 | | Manufacturer | AtriCure, Inc.
6033 Schumacher Park Drive
West Chester, OH 45069 | | | Contact | Elsa Abruzzo
Vice President, Clinical and Regulatory Affairs | | #### Intended Use The AtriCure Ablation System is intended to ablate soft tissues during general surgery using radiofrequency energy. #### Predicate Devices The predicate devices for the AtriCure Ablation System are the AtriCure Bipolar System (K020919), the AtriCure Transpolar™ System (K052893), and the Medtronic Cardioablate Surgical Ablation System (K060400) #### Device Description The AtriCure Ablation System includes a hand held, single use, bipolar radiofrequency (RF) surgical instrument (Isolator® Transpolar Clamps or Isolator Synergy™ Clamps) intended for the ablation of soft tissues and an accessory instrument guide (Glidepath™ Tape). The clamp handpieces are connected via an integral cable to the AtriCure re-useable Ablation and Sensing Unit (ASU2) or an Isolator Switch Matrix (ASB3) console. #### Materials All materials in the AtriCure Ablation System are suitable for their intended use and have been used in numerous previously cleared products. Testing was conducted in Accordance with ISO 10993-1 to ensure appropriate biocompatibility of all materials. #### Testing Appropriate product testing was conducted to evaluate conformance to product specification and substantial equivalence to predicate devices. #### Summary of Substantial Equivalence The AtriCure Ablation System is equivalent to the predicate products. The indications for use, basic overall function, and materials used are substantially equivalent. {1}------------------------------------------------ Image /page/1/Picture/11 description: The image shows the logo for the U.S. Department of Health & Human Services. The logo consists of a stylized eagle with its wings spread, and the words "DEPARTMENT OF HEALTH & HUMAN SERVICES - USA" are arranged in a circle around the eagle. The eagle is black, and the text is also black. The logo is simple and recognizable. Food and Drug Administration 9200 Corporate Boulevard Rockville MD 20850 Regulatory Technology Services, LLC % Mr. Mark Job Responsible Third Party Official 1394 25th Street, NW Buffalo, Minnesota 55313 Re: K063630 Trade/Device Name: Atricure Ablation System Regulation Number: 21 CFR 878.4400 Regulation Name: Electrosurgical cutting and coagulation device and accessories Regulatory Class: Class II Product Code: GEI Dated: December 4, 2006 Received: December 6, 2006 Dear Mr. Job: We have reviewed your Section 510(k) premarket notification of intent to market the device referenced above and have determined the device is substantially equivalent (for the indications for use stated in the enclosure) to legally marketed predicate devices marketed in interstate commerce prior to May 28, 1976, the enactment date of the Medical Device Amendments, or to devices that have been reclassified in accordance with the provisions of the Federal Food, Drug, and Cosmetic Act (Act) that do not require approval of a premarket approval application (PMA). You may, therefore, market the device, subject to the general controls provisions of the Act. The general controls provisions of the Act include requirements for annual registration, listing of devices, good manufacturing practice, labeling, and prohibitions against misbranding and adulteration. If your device is classified (see above) into either class II (Special Controls) or class III (PMA), it may be subject to such additional controls. Existing major regulations affecting your device can be found in the Code of Federal Regulations, Title 21, Parts 800 to 898. In addition, FDA may publish further announcements concerning your device in the Federal Register. Please be advised that FDA's issuance of a substantial equivalence determination does not mean that FDA has made a determination that your device complies with other requirements of the Act or any Federal statutes and regulations administered by other Federal agencies. You must comply with all the Act's requirements, including, but not limited to: registration and listing (21 CFR Part 807); labeling (21 CFR Part 801); good manufacturing practice requirements as set forth in the quality systems (QS) regulation (21 CFR Part 820); and if applicable, the electronic product radiation control provisions (Sections 531-542 of the Act); 21 CFR 1000-1050. {2}------------------------------------------------ Page 2 - Mr. Mark Job This letter will allow you to begin marketing your device as described in your Section 510(k) premarket notification. The FDA finding of substantial equivalence of your device to a legally marketed predicate device results in a classification for your device and thus, permits your device to proceed to the market. If you desire specific advice for your device on our labeling regulation (21 CFR Part 801), please contact the Office of Compliance at (240) 276-0115 Also, please note the regulation entitled, "Misbranding by reference to premarket notification" (21CFR Part 807.97). You may obtain other general information on your responsibilities under the Act from the Division of Small Manufacturers, International and Consumer Assistance at its toll-free number (800) 638-2041 or (240) 276-3150 or at its Internet address http://www.fda.gov/cdrh/industry/support/index.html. Sincerely yours, Mark N. Melkerson Director Division of General, Restorative and Neurological Devices Office of Device Evaluation Center for Devices and Radiological Health Enclosure {3}------------------------------------------------ # Indications for Use 510(k) Number (if known): __ 1061630 Device Name: AtriCure Ablation System Indications For Use: The AtriCure Ablation System is intended to ablate soft tissues during general surgery using radiofrequency energy. Prescription Use (Part 21 CFR 801 Subpart D) AND/OR Over-The-Counter Use (21 CFR 807 Subpart C) (PLEASE DO NOT WRITE BELOW THIS LINE-CONTINUE ON ANOTHER PAGE IF NEEDED) Concurrence of CDRH, Office of Device Evaluation (ODE) Styph. Rood ision Sign-Off) "sion of General, Restorative and Neurological Devices Number K063630 Page 1 of 1 --- **Source:** [https://fda.innolitics.com/submissions/SU/subpart-e%E2%80%94surgical-devices/GEI/K063630](https://fda.innolitics.com/submissions/SU/subpart-e%E2%80%94surgical-devices/GEI/K063630) **Published by [Innolitics](https://innolitics.com)** — a medical-device software consultancy. We help companies design, build, and clear FDA-regulated software and AI/ML devices. If you're preparing [a 510(k)](https://innolitics.com/services/510ks/), [a De Novo](https://innolitics.com/services/regulatory/), [a SaMD](https://innolitics.com/services/end-to-end-samd/), [an AI/ML medical device](https://innolitics.com/services/medical-imaging-ai-development/), or [an FDA regulatory strategy](https://innolitics.com/services/regulatory/), [get in touch](https://innolitics.com/contact). **Cite:** Innolitics at https://innolitics.com